Antineoplaston A10/antineoplaston As2-1

Drug Profile

Antineoplaston A10/antineoplaston As2-1

Alternative Names: A10; A10 I; ANP; Antineoplastons A10/AS2-1; Antineoplastons therapy; AS2-1; Astugenal (AS2-1); Atengenal (A10); NSC-620261; NSC-648539

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Burzynski Research Institute
  • Class Amino acids; Antineoplastics; Antineoplastons; Benzeneacetamides; Phenylacetates; Piperidones
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Anaplastic astrocytoma; Glioma
  • No development reported Cancer

Most Recent Events

  • 07 Dec 2016 Discontinued - Phase-II for Glioma (Metastatic disease, Adjuvant therapy) in USA (IV) (NCT02988726)
  • 01 Apr 2016 Burzynski Research Institute initiates a phase-II clinical trial in Glioma (In infants, In children, In adolescents, In adults, In the elderly) in USA (IV) (NCT02742883)
  • 16 Apr 2015 Interim adverse events data from a phase II trial in Glioma released by Burzynski Research Institute
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top